Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 4, 2005, Pages 418-421

  Flisiak, I ^a   Mysliwiec H ^a   Chodynicka, B ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

MMP 1; Psoriasis; Skin diseases; TIMP 1; Treatment

Indexed keywords

ANTIPSORIASIS AGENT; DITHRANOL; INTERSTITIAL COLLAGENASE; SALICYLIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 21744440269     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01199.x     Document Type: Article

References (24)

1. Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Derm Venereol 2003; 17: 1-5.
2. Kadunce DP, Krueger GG. Pathogenesis of psoriasis. Dermatol Clin 1995; 13: 723-737.
3. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the Pathogenesis of psoriasis. J Invest Dermatol 1990; 94: 135-140.
4. Kondo S, Hozumi Y, Maejima H, Aso K. Organ culture of psoriatic skin: effect of TGF-alpha and TGF-beta on epidermal structure in vitro. Arch Dermatol Res 1992; 284: 150-153.
5. Powell TJ, Ben-Bassat H, Klein BY et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999; 141: 802-810.
6. Prinz JC. The role of T cells in psoriasis. J Eur Acad Derm Venereol 2003; 17: 257-270.
7. Furue M, Kato M, Nakamura K et al. Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. Int J Cancer 1997; 71: 505-509.
8. Leivo T, Leivo I, Kariniemi AL et al. Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. Br J Dermatol 1998; 138: 57-62.
9. Wang XJ, Greenhalgh DA, Bickenbach JR et al. Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci USA 1997; 94: 2386-2391.
10. Wataya-Kaneda M, Hashimoto K, Kato M et al. Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. J Dermatol Sci 1996; 11: 183-188.
11. Flisiak I, Chodynicka B, Porȩbski P, Flisiak R. Association between psoriasis severity and transforming growth factor beta1 and beta2 in plasma and scales from psoriatic lesions. Cytokine 2002; 19: 121-125.
12. Flisiak I, Porȩbski P, Flisiak R, Chodynicka B. Plasma transforming growth factor beta 1 as a biomarker of psoriasis activity and treatment efficiency. Biomarkers 2003; 8: 437-443.
13. Feliciani C, Vitullo P, D'orazi G et al. The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions. Exp Dermatol 1997; 6: 321-327.
14. Buisson-Legendre N, Emonard H, Bernard P, Hornebeck W. Relationship between cell-associated matrix metalloproteinase 9 and psoriatic keratinocyte growth. J Invest Dermatol 2000; 115: 213-218.
15. Fleischmajer R, Kuroda K, Hazan R, et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol 2000; 115: 771-777.
16. Suomela S, Kariniem AL, Snellman E, Saarialho-Kere U. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp Dermatol 2001; 10: 175-183.
17. Suomela S, Kariniemi AL, Impola U et al. Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis. Acta Derm Venereol 2003; 83: 108-114.
18. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
19. Savolainen L, Kontinen J, Alatalo E et al. Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Derm Venereol 1998; 78: 466-467.
20. Zhang B-B, Cai W-M, Weng H-L et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-β1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003; 9: 2490-2496.
21. Nakamura T, Ushiyama C, Suzuki S et al. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 2000; 20: 32-36.
22. Lein M, Nowak L, Jung K et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997; 30: 491-496.
23. Myers A, Lakey R, Cawston TE et al. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology 2004; 43: 272-276.
24. Bhagavathula N, Nerusu KC, Lal A et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122: 130-139.